Breakthrough therapy: FDA's new designation for accelerating approval of promising pipeline therapies.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 275
- By:
- Publication type:
- Article
Works matching IS 1082801X AND DT 2013 AND VI 48 AND IP 8
Results: 24
1
2
Weekly exenatide treatment yields better glycemic control, weight loss than treatment with insulin glargine.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 274
- Publication type:
- Article
3
Once-weekly exenatide is an alternative treatment to daily basal insulin.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 274
- Publication type:
- Article
4
Study finds that dapagliflozin demonstrates glycemic responses similar to other oral agents.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 273
- Publication type:
- Article
5
Lower risk of heart failure and stroke with exenatide than with insulin.
- Published in:
- 2013
- Publication type:
- Proceeding
6
Study finds that dapagliflozin produces similar glycemic efficacy to glipizide.
- Published in:
- 2013
- Publication type:
- Proceeding
7
Patients with type 2 diabetes, history of CV events have high rates of additional CV events.
- Published in:
- 2013
- Publication type:
- Proceeding
8
International study finds that dapagliflozin has metabolic benefits.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 271
- Publication type:
- Article
9
Examining medication reconciliation from a perspective of safety.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 266
- By:
- Publication type:
- Article
10
Oral oncolytics: Assessing value of newer agents versus current standards of care as part of P&T processes.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 258
- By:
- Publication type:
- Article
11
FDA actions in brief.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 257
- Publication type:
- Article
12
First-time generic approvals.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 257
- Publication type:
- Article
13
New molecular entity.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 256
- Publication type:
- Article
14
Pipeline preview.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 256
- Publication type:
- Article
15
Ample vaccine supply key to combatting unpredictability of flu season.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 255
- Publication type:
- Article
16
Rise in mortality risk seen in hysterectomized women aged 50 to 59 not using estrogen therapy.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 254
- By:
- Publication type:
- Article
17
Unauthorized prescribers bill Part D $5 million.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 253
- By:
- Publication type:
- Article
18
Without optimal treatment, episodic migraine may progress to chronic migraine.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 252
- Publication type:
- Article
19
Triptans widely prescribed but contraindicated in patients with CV conditions.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 251
- Publication type:
- Article
20
Health economic analysis shows canagliflozin monotherapy may reduce costs of type 2 diabetes.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 249
- By:
- Publication type:
- Article
21
Concomitant control of BP, cholesterol is difficult.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 248
- Publication type:
- Article
22
Responsible use of drugs could save $200B annually.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 247
- By:
- Publication type:
- Article
23
Guideline adds aromatase inhibitor for breast cancer prevention.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 243
- Publication type:
- Article
24
Adherence varies across market segments.
- Published in:
- Formulary, 2013, v. 48, n. 8, p. 250
- Publication type:
- Article